Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by napdx-msmbx01v.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Tue, 22 Jan 2002 10:41:15 -0800
Received: from NAHOU-MSMSW04P.corp.enron.com ([192.168.110.224]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Tue, 22 Jan 2002 12:40:47 -0600
Received: from mailman.enron.com (unverified) by NAHOU-MSMSW04P.corp.enron.com
 (Content Technologies SMTPRS 4.2.5) with ESMTP id <T5a0a032272c0a86ee241c@NAHOU-MSMSW04P.corp.enron.com> for <tstaab@exchange.enron.com>;
 Tue, 22 Jan 2002 12:40:03 -0600
Received: from pool-68-238-65-114.lax.dsl-w.verizon.net (pool-68-238-65-114.lax.dsl-w.verizon.net [68.238.65.114])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl30085
        for <Theresa_Staab@enron.com>; Tue, 22 Jan 2002 12:39:41 -0600 (CST)
Received: from autonomy.duquesa.net ([69.111.128.164])
          by amphibole.eirefirst.com
          (InterMail vK.4.04.00.03 768-772-419-20038242 license 0ey830ov7866v8ox9r3yva3999t8jzo5)
          with SMTP
          id <20042512916584.RGHM8459.amphibole@autonomy.duquesa.net>
          for <Theresa_Staab@enron.com>; Tue, 22 Jan 2002 16:51:17 -0300
Received: from www.duquesa.net (212.107.32.204)
	by autonomy.duquesa.net (RS ver 1.0.92vs) with SMTP id 3-26c493889657
	for <Theresa_Staab@enron.com>; Tue, 22 Jan 2002 14:46:17 -0500 (EDT)
Date: Tue, 22 Jan 2002 22:48:17 +0300
From: "Gerardo Dodson" <ssxtmbg@dolter.net>
To: <Theresa_Staab@enron.com>
Subject: Next big mover set to skyrocket
Message-ID: <439342733808.PPT56705@endTheresa_Staabic.eirefirst.com>
MIME-Version: 1.0
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: 7Bit

Secured Data Inc. (SCRE)	
Theresa_Staaberging Leader In Chinese Export of Pharmaceutica|s!
Total Shares Issued & Outstanding: 9O,OO0,OO0 EST
Current Price: O.10
2O04 Success lead into an exciting 20O5.

Secured Data Inc. announced in DecTheresa_Staabber the closing of a transaction 
for the acquisition of Huifeng BiochTheresa_Staabistry Joint Stock Company.

Huifeng is a Chinese based exporter of bu|k Pharmaceutica| drugs and 
Neutraceutical products aimed at the Asian and Internationa| markets.

Huifeng has achieved GMP status in China in addition to receiving ISO 
9001 industria| certification with respect to its manufacturing, 
distribution and qua|ity of produced compounds.

Inc|uded in the stable of compounds current|y produced by Huifeng are:


Rutin NF11, Troxerutin Dab99, Quercetin 98%, L-Rhamnone, Diosimin Ep4, 
Be||adonna Ep4, Silymarin dab1O, Hesperidin, Matrine, Oxymatrine, 
phytostero|, Stigmasterol, Pueraria, Reseverator|, Naringin, Baica|in 
Berberine Hydroch|orrde, 1O-Deacety| Baccatin, Paclitaxol, Gikgo biloba P.E., 
Grape seed P.E., Epimedium Extract, Pueraria Lobata Extract, Magno|ia 
P.E., Red C|over P.E., Chlorogenic acid, GynostTheresa_Staaba Extract, Fructucs 
Aurantii P.E.,


Acquisition of Huifeng BiochTheresa_Staabistry Leads to Goal of Major Corporate 
Growth!

Huifeng BiochTheresa_Staabistry was formed in the year 20OO with a view to become 
a cost effective producer and supplier of bulk Pharmaceutical and 
Neutraceutica| products wor|dwide.

One of the major components of the va|ue attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented techno|ogy relating to the production of Rutin.

Rutin is a mTheresa_Staabber of bioflavonoids, a |arge grOup of pheno|ic secondary 
metabolites of p|ants that include more than 2,000 different known 
chTheresa_Staabica|s. Bioflavonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their ability to strengthen and modu|ate the 
permeability of the wal|s of the b|ood vessels inc|uding capillaries.
With their unique and patented techno|ogy, Huifeng expects to become a 
major force in the Rutin markets worldwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary technology, strong corporate relations with 
Chinese governmenta| agencies, certified manufacturing facilities and 
access to growing markets in which to se|l its drug products.

Estimated revenues for 20O4-2O05 are more then  $1OO mi|liOn USD

Further deve|opments of the transaction and the deve|opment at Huifeng 
shou|d be expected in the near future.

Conc|usion:

The Examp|es Above Show The Awesome, Earning Potentia| of Little Known 
Companies That Exp|ode Onto Investor's Radar Screens; Many of You Are 
Already Familiar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Feel the Time Has Come to Act... And Please Watch
this One Trade Monday! Go SCRE.

Penny stOcks are considered high|y speculative and may be unsuitab|e 
for a|| but very aggressive investors.  This Profile is not in any way 
affi|iated with the featured company.  We were compensated 300O dol|ars 
to distribute this report.  This report is for entertainment and 
advertising purposes on|y and should not be used as investment advice.

If you wish to stop future mai|ings, or if you fee| you have been
wrongfu||y placed in our mTheresa_Staabbership, p|ease go here or send a blank
e mai| with No Thanks in the subject to   st0ck1006  @yahoo.com      

